The American Society of Echocardiography (ASE) and Cardiovascular Research Foundation^® (CRF^®) are pleased to announce a new educational collaboration to foster shared learning, drive innovation, and strengthen connections across the cardiovascular community.

In a new study from Boston University Chobanian & Avedisian School of Medicine, researchers have identified a protein called non-structural protein 15 (nsp15) that plays a key role in helping SARS-CoV-2 hide from the body’s defenses by suppressing the production of viral double-stranded (dsRNA), leading to increased viral replication while limiting the body’s immune response.

Improved understanding of social determinants of health 

— 

EULAR – The European Alliance of Associations for Rheumatology – acknowledges the impact of socioeconomic factors on the persistence of rheumatic and musculoskeletal diseases (RMD), and the society’s manifesto includes tackling lifestyle determinants, promoting active ageing, and developing RMD education and communication programmes.¹ Health literacy has also been flagged as central to the prevention and control of noncommunicable diseases – including RMD – by the World Health Organization.² 

According to a new study, presented at the American College of Cardiology (ACC) Care of the Athletic Heart 2025 conference, sleep apnea may be more prevalent in younger female athletes than previously believed, especially among female athletes with higher levels of training. While obstructive sleep apnea has been observed in younger male athletes, the prevalence in female athletes and the association with cardiovascular risk is largely unknown.

While the U.S. has recently seen a welcome downturn in drug overdose deaths, a new study from Northwestern Medicine is the first to pinpoint when the tide began to turn — identifying August 2023 as the national inflection point in the crisis.

By creating a cohesive AI-enabled and physics-based molecular modeling and drug discovery pipeline built around film industry animation software, researchers at the Wyss Institute at Harvard University identified the orally available, FDA-approved drug bemcentinib, as a potential antiviral agent. They then used this chemical compound as a launch pad for developing a more specific and effective antiviral drug with efficacy against a broad range of coronaviruses, which has great potential for fighting future respiratory pandemics.